Research stack

CJC-1295 + Ipamorelin Slow-Wave Sleep Protocol

Pre-bed GHRH + GHRP pulse used for characterized slow-wave sleep effects.

Component peptides

The short-acting variant of CJC-1295 — a GHRH(1-29) analog with four amino-acid substitutions for degradation resistance but without the maleimidopropionic-acid moiety that produces albumin binding. Half-life on the order of 30 minutes, in contrast to the DAC version's multi-day exposure.

Ipamorelin

A pentapeptide growth-hormone secretagogue that binds the ghrelin/GHS-R1a receptor, reported as one of the most selective GH-releasers with minimal effect on cortisol or prolactin.

Goal

Pre-bed GHRH + GHRP pulse for characterized slow-wave sleep effects.

Peptides

CJC-1295 (no-DAC), Ipamorelin

Why it works

GHRH-analog signalling increases slow-wave sleep duration, and combined GHRH + GHRP produces synergistic pulsatile GH release aligned with the natural nocturnal pulse.

How to use

CJC-1295 (no-DAC) — 100 mcg subcutaneous pre-bed.
Ipamorelin — 100-300 mcg subcutaneous pre-bed, co-administered.

Last updated: 2026-09-15

Component peptides	CJC-1295 no DAC + Ipamorelin
Duration reported	8 weeks
Cycle pattern	8 weeks on, 4 weeks off
Difficulty	foundational
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.